BSX Q3 2026 Earnings Analysis
Boston Scientific reported Q3 revenue of $5.14B (+1.5% organic) and EPS of $0.73 (-3%), impacted by cyber incident; 2027 expected as trough year with restructuring and new launches driving 2028 recovery.
Key Metrics
Wichtigste Erkenntnisse
- Cyber incident reduced Q3 sales ~300 bps (~$150M) and EPS by $0.07; 200-300 bps impact expected in Q4.
- Watchman and EP markets weakening; 2027 projected as trough year with no growth as China pricing pressure intensifies.
- $500M restructuring over 3 years with >50% savings by 2027; new product launches in 2028-2029 drive recovery.
Anhören auf
Verfügbar in
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, here with Jordan, and today we're diving into Boston Scientific's third quarter 2026 results. And Jordan, I'll be honest—this one's a bit of a bumpy ride.
Yeah, there's a lot to unpack here. Cybersecurity incident, competitive pressure, a 2027 outlook that's basically "buckle up." Should be a good one.
Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Alright, let's get into the numbers.
So Boston Scientific reported Q3 revenue of $5.14 billion, up just 1.5% year-over-year. That's well below their original guidance of 3% to 5% growth. Adjusted EPS came in at $0.73, down 3% versus last year, and below the $0.80 to $0.82 range they'd guided to.
And the big culprit here is that cybersecurity incident they flagged. Management estimates it knocked about 300 basis points off revenue growth and cost them roughly $0.07 in EPS. There was an eight-business-day outage where they literally couldn't manufacture or ship product.
Right, and the good news is operations were fully back up by September 8th. But here's the kicker—the pain doesn't stop there. They're guiding Q4 revenue to actually decline, somewhere between down 1% and down 3%, partly because customers over-ordered at the end of Q3 to restock, and now that inventory has to burn off.
That gives you full-year 2026 organic growth of about 3.75%, and EPS of $3.16 to $3.18. Not the year they were hoping for, clearly.
And honestly, Jordan, the headline that's going to dominate conversations isn't even Q3 or Q4—it's what they said about 2027.
Yeah, this is the part investors need to sit up for. Management straight-up said they expect to be challenged to grow both sales and adjusted EPS in 2027, excluding the pending Penumbra acquisition. They're calling it a "transition year" and expect 2027 to be the trough before things stabilize.
So what's actually driving that? Two words: Watchman and EP.
Electrophysiology, for anyone who needs the refresher—that's their heart rhythm mapping and ablation business, home to their FARAPULSE platform. It's been a huge growth engine for years, but EP sales declined 5% this quarter, with an 8% drop in the U.S. Management says they're losing share to new competitors with different PFA, or pulsed field ablation, technologies, and that erosion is expected to continue until they launch their next-gen FARAWAVE Ultra catheter—which got pushed back to early 2028.
And Watchman, their left atrial appendage closure device, isn't much better. Sales there dropped 7% in the U.S., though it grew 4% internationally. Standalone procedures were down nearly 20%.
Management thinks part of that is physicians digesting new clinical data and changing referral patterns, not necessarily a loss of confidence in the device. But there's also a new competitive launch coming in 2027, which they're baking into their conservative outlook.
So what are they doing about all this? This is where it gets interesting strategically.
They announced a company-wide restructuring program—CFO John Monson said they expect over $500 million in savings over the next three years, with more than half of that realized by the end of 2027. It touches org structure, supply chain, back-office consolidation, even things like travel and vendor spend.
There's also a notable pivot on their Vitalist circulatory support device. Instead of chasing high-risk PCI procedures, they're refocusing on treating cardiogenic shock—a space with brutal unmet need, since mortality there approaches 50%. And to fund that R&D, they struck a partnership with Blackstone Life Sciences, who'll get royalties down the road in exchange for funding development now.
Smart move, honestly. It lets them keep a major R&D program alive without draining capital they need elsewhere.
And let's not forget the Penumbra acquisition looming in the background. That deal's now expected to close in early 2027, a bit later than hoped, due to regulatory review. But management was clearly bullish—CEO Mike Mahoney called it a strong complement to their cardiovascular business.
One thing I appreciated in the Q&A was the candor. CFO John Monson basically admitted, "we need to rebuild confidence in our forecast." That's a pretty direct acknowledgment after multiple guidance misses this year. They talked about adding more scenario analysis and third-party data to tighten up forecasting.
Mahoney also laid out a roadmap: 2027 is the trough, 2028 should bring a return to "high performance," and 2029 should see further acceleration—driven by new launches across EP, Watchman's next-gen platform, and a new defibrillator line called Denali in cardiac rhythm management.
Meanwhile, it's worth noting that about 75% of the business—things like interventional cardiology, vascular therapies, and neuromodulation—is still growing nicely, with interventional cardiology up 19% this quarter. The core business isn't broken; it's really concentrated pressure in two segments plus some China pricing headwinds dragging down the overall picture.
So bottom line for investors: this is a company saying "trust us, 2027 is a dip, not a decline." The restructuring and Blackstone partnership show they're trying to protect the balance sheet while still funding growth bets.
Before we wrap, I need to add our closing disclaimer: everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. So keep an eye on Q4 earnings and the formal 2027 guidance coming in January—that'll tell us whether this trough narrative holds up.
And watch those EP and Watchman trends closely—they're the swing factors here.
That's it for this episode of Beta Finch. Thanks for listening, and we'll catch you next time as we break down more earnings calls.
See you then!